Neuro-Ophthalmology News

SEATTLE – Inebilizumab was shown to be safe and effective in preventing relapses in individuals with neuromyelitis optica spectrum disorder, a speaker said at the 2022 American Academy of Neurology annual meeting.

A significant improvement of visual acuity was reported in eyes treated with a unilateral intravitreal injection of lenadogene nolparvovec for Leber hereditary optic neuropathy, researchers reported at the 2022 American Academy of Neurology annual meeting.

Natalia S. Rost, MD, MPH, chair of the AAN science committee, led a discussion to highlight select studies being presented at the AAN’s annual meeting April 2-7 in Seattle.

High alcohol use was associated with more severe neurodegeneration and smoking was linked with greater probability of MS diagnosis, according to a U.K. study published in JAMA Network Open.

In a company release, Horizon Therapeutics announced results from a phase 2/3 trial demonstrating that its B-cell-depleting agent Uplizna reduced the severity of attacks in people with neuromyelitis optica spectrum disorder.

Uplizna appeared to benefit patients with neuromyelitis optica spectrum disorder who were previously treated with rituximab, according to study results published in Multiple Sclerosis and Related Disorders.

Chugai Pharmaceutical Co. released data showing Enspryng had a favorable benefit-risk profile and effectively reduced relapses over 4 years of treatment among people with a form of neuromyelitis optica spectrum disorder.

Horizon Therapeutics plc announced results of a retrospective analysis that showed Uplizna appeared to offer durable efficacy and a favorable safety profile for African American patients with neuromyelitis optica spectrum disorder.

A survey of community neurologists demonstrated four primary themes associated with the impact of the COVID-19 pandemic in this group, specifically highlighting “the unusual environment” in which these providers practice.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended Enspryng to be approved to treat neuromyelitis optica spectrum disorder in people aged 12 years and older, according to a Roche press release.